Thus, co-occurring mutations in BTK and PLCG2 have been shown to mediate ibrutinib resistance (50), while a point mutation in BCL2 has recently been identified in patients with CLL resistant to treatment with venetoclax (19). Here, BTK is linked to B-cell chronic lymphocytic leukemia.